Direkt zum Inhalt
Merck

1292303

USP

Glimepirid

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

Glimepirid

Slide 1 of 1
Anmelden Preise für Organisationen und Verträge anzeigen

Größe auswählen

200 MG

CHF 641.00

CHF 641.00

Warenkorb auf Verfügbarkeit prüfen
Großbestellung anfragen

Über diesen Artikel

Empirische Formel (Hill-System):
C24H34N4O5S
CAS-Nummer:
93479-97-1
Molekulargewicht:
490.62
MDL-Nummer:
MFCD00878417
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329749940
NACRES:
NA.24

Wichtige Dokumente

Gesamtdokumentation anzeigen

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

Qualität

pharmaceutical primary standard

API-Familie

glimepiride

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

InChIKey

WIGIZIANZCJQQY-RUCARUNLSA-N

Angaben zum Gen

human ... ABCC8(6833), KCNJ11(3767)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
Y0000515BP1144Y0000516
Glimepirid United States Pharmacopeia (USP) Reference Standard

USP

1292303

Glimepirid

Glimepirid European Pharmacopoeia (EP) Reference Standard

Y0000515

Glimepirid

Glimepirid British Pharmacopoeia (BP) Reference Standard

BP1144

Glimepirid

Glimepirid für die Systemeignung European Pharmacopoeia (EP) Reference Standard

Y0000516

Glimepirid für die Systemeignung

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

BP

manufacturer/tradename

EDQM

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

pharmaceutical (small molecule)

API family

glimepiride

API family

glimepiride

API family

glimepiride

API family

glimepiride

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Glimepirid wird derzeit zur Behandlung von Typ-2-Diabetes eingesetzt.
Glimepiride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Glimepiride Tablets
  • Pioglitazone and Glimepiride Tablets

Biochem./physiol. Wirkung

Glimepirid ist ein wirksamer Blocker kardialer KATP-Kanäle, aktiviert durch Pinacidil mit einem IC50 von 6,8 nM.
Wirksamer Blocker kardialer KATP-Kanäle.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Vergleichbares Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1292325

Glimepiride Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0000515

Glimepirid, European Pharmacopoeia (EP) Reference Standard

1292314

Glimepirid-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1292336

Glimepirid-verwandte Verbindung C, United States Pharmacopeia (USP) Reference Standard

1292347

Glimepirid-verwandte Verbindung D, United States Pharmacopeia (USP) Reference Standard

Y0001742

Glimepirid für die Identifizierung von Unreinheit A, European Pharmacopoeia (EP) Reference Standard

PHR1727

N-[[4-[2-[[(3-Ethyl-2,5-dihydro-4-methyl-2-oxo-1H-pyrrol-1-yl)carbonyl]amino]ethyl]phenyl]sulfonyl]carbamidsäuremethylester, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1725

Glimepirid cis-Isomer (Glimepirid-verwandte Verbindung A), Pharmaceutical Secondary Standard; Certified Reference Material

BP1144

Glimepirid, British Pharmacopoeia (BP) Reference Standard

PHR1726

Glimepiride Sulfonamide, pharmaceutical secondary standard, certified reference material

Piktogramme

Health hazard
GHS08

Signalwort

Warning

H-Sätze

H361

Gefahreneinstufungen

Repr. 2

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

J Rosenstock et al.
Diabetes care, 19(11), 1194-1199 (1996-11-01)
To compare the efficacy and safety of two daily doses of the new sulfonylurea, glimepiride (Amaryl), each as a once-daily dose or in two divided doses, in patients with NIDDM. Of the previously treated NIDDM patients, 416 entered this multicenter
Stephen N Davis
Journal of diabetes and its complications, 18(6), 367-376 (2004-11-09)
Type 2 diabetes mellitus, a disorder of impaired insulin secretion and insulin resistance, has reached epidemic proportions. The effective management of Type 2 diabetes is of vital concern to clinicians. The identification of high-risk individuals and lifestyle management can help
Vanessa J Briscoe et al.
Expert opinion on drug metabolism & toxicology, 6(2), 225-235 (2010-01-09)
Type 2 diabetes mellitus (T2DM) is increasingly prevalent throughout the world; controlling glycemia is an important part of preventing serious complications of diabetes. Sulfonylureas have been used in the treatment of type 2 diabetes for many years. This article reviews
Mary T Korytkowski
Pharmacotherapy, 24(5), 606-620 (2004-05-28)
Sulfonylureas, which have evolved through two generations since their introduction nearly 50 years ago, remain the most frequently prescribed oral agents for treatment of patients with type 2 diabetes mellitus. Glyburide, glipizide, and glimepiride, the newest sulfonylureas, are as effective
T F Veneman et al.
The Netherlands journal of medicine, 52(5), 179-186 (1998-07-04)
Disturbances in insulin secretion and insulin action are both involved in the pathophysiology of type 2 (or non-insulin-dependent) diabetes mellitus. The newly developed sulfonylurea (SU) derivative glimepiride has a marked insulin secretory effect both in vitro and in vivo, and
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung